MedPath

Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients.

Phase 2
Conditions
metastatic breast carcinoma
Registration Number
JPRN-UMIN000013045
Lead Sponsor
Japan Breast Cancer Research Network
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

ECOG performance status is more than 3

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
patient preference
Secondary Outcome Measures
NameTimeMethod
PFS, OS, address quality of life (EORTC-30), and anxiety and depression (HADS)
© Copyright 2025. All Rights Reserved by MedPath